Shots: The approval is based on two P-III studies assessing Orilissa 150 mg qd and 200 mg bid vs PBO enrolling 1,700 women with moderate to severe endometriosis pain P-III studies Results: showed reduction in daily menstrual pain and non-menstrual pelvic pain @6mos.; reduction in numeric rating scale (NRS) scores @3mos.; reduction in pain during […]Read More
